EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Samantha M Ruff, Ashish Manne iD, Jordan M Cloyd, Mary Dillhoff, Aslam Ejaz, Timothy M Pawlik iD

Current Oncology · 18.06.2023 · 30 (6) · 5863-5875

DOI: 10.3390/curroncol30060439 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 18.06.2023. Verfasst von Samantha M Ruff und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The liver maintains a balance between immune tolerance and activation in its role as a filtration system. Chronic inflammation disrupts this immune microenvironment, thereby allowing for the rise and progression of cancer. Hepatocellular carcinoma (HCC) is a liver tumor generally diagnosed in the setting of chronic liver disease. When diagnosed early, the primary treatment is surgical resection, liver transplantation, or liver directed therapies. Unfortunately, patients with HCC often present at an advanced stage or with poor liver function, thereby limiting options. To further complicate matters, most systemic therapies are relatively limited and ineffective among patients with advanced disease. Recently, the IMbrave150 trial demonstrated that the combination of atezolizumab and bevacizumab was associated with better survival compared to sorafenib among patients with advanced HCC. As such, atezolizumab and bevacizumab is now recommended first-line therapy for these patients. Tumor cells work to create an immunotolerant environment by preventing the activation of stimulatory immunoreceptors and upregulating expression of proteins that bind inhibitory immunoreceptors. ICIs work to block these interactions and bolster the anti-tumor function of the immune system. We herein provide an overview of the use of ICIs in the treatment of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmune Checkpoint InhibitorsBevacizumabTumor Microenvironment

Stichwörter der Autor:innen

cirrhosishepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyliver

Substanzen

Immune Checkpoint InhibitorsBevacizumab

Autor:innen und Institutionen

  • Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
  • Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

ORCID-Profile: Ashish Manne, Timothy M Pawlik

Zitieren

APA

Ruff, S. M., Manne, A., Cloyd, J. M., Dillhoff, M., Ejaz, A., & Pawlik, T. M. (2023). Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Current Oncology, 30(6), 5863-5875. https://doi.org/10.3390/curroncol30060439

Vancouver

Ruff SM, Manne A, Cloyd JM, Dillhoff M, Ejaz A, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Current Oncology. 2023;30(6):5863-5875. doi:10.3390/curroncol30060439

BibTeX
@article{Ruff2023,
  author = {Ruff, Samantha M and Manne, Ashish and Cloyd, Jordan M and Dillhoff, Mary and Ejaz, Aslam and Pawlik, Timothy M},
  title = {Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {6},
  pages = {5863--5875},
  doi = {10.3390/curroncol30060439}
}
Kostenlos starten →